We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > biologic medicines

News List

Samsung Bioepis Opens New Headquarters contractpharma
January 26, 2021
The 52,000-square-foot campus to become the hub of Samsung Bioepis’ drive for accelerated development of next-gen biologic medicines.
Michigan Governor Snyder Signs Bill Facilitating Patient Access to Interchangeable Biologic Medicine biospace
March 05, 2018
The Biotechnology Innovation Organization (BIO) and MichBio commend Governor Rick Snyder for signing critical legislation to create a pathway for the substitution of interchangeable biologic medicines, with appropriate communication to patients and physi
EMA to review Sandoz biosimilars adalimumab and infliximab europeanpharmaceuticalreview
June 05, 2017
Sandoz, a Novartis division, announced that the European Medicines Agency (EMA) has accepted for regulatory review their marketing authorisation applications for biosimilars to AbbVie‘s Humira (adalimumab) and Janssen‘s Remicade (infliximab)...